Patients without baseline CNS metastases were randomly assigned ( 1:1 ) to receive lapatinib-capecitabine ( lapatinib 1,250 mg per day ; capecitabine 2,000 mg/m ( 2 ) per day on days 1 to 14 every 21 days ) or trastuzumab-capecitabine ( trastuzumab loading dose of 8 mg/kg followed by an infusion of 6 mg/kg every 3 weeks ; capecitabine 2,500 mg/m ( 2 ) per day on days 1 to 14 every 21 days ) .